Trial Profile

A Phase 1 Therapeutic Trial of Novel Radiopharmaceutical MNPR-101-Lu in Advanced Cancers

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MNPR 101 Lu 177 (Primary)
Indications Solid tumours
Focus Adverse reactions

Most Recent Events

25 Aug 2024 New trial record
21 Aug 2024 According to Monopar Therapeutics media release, the company has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu.which is currently scheduled to launch in the fourth quarter of this calendar year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com